SELLAS Life Sciences (SLS) Cash & Equivalents (2010 - 2026)
SELLAS Life Sciences (SLS) reported Cash & Equivalents of $100000.0 for Q1 2026, little changed year-over-year from $100000.0 in Q1 2025, and little changed quarter-over-quarter from $100000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Cash & Equivalents (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Cash & Equivalents data on file, last reported at $100000.0 in Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $100000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $100000.0 (changed 0.0% YoY), and the FY2025 annual result was $100000.0, down 99.28% from the prior year.
- Cash & Equivalents held at $100000.0 in Q1 2026 per SLS's latest filing, from $100000.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $44.3 million in Q3 2025 and troughed at $100000.0 in Q1 2022.
- A 5-year average of $6.3 million and a median of $100000.0 in 2022 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 99.64% in 2022, then jumped 44220.0% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $17.1 million in 2022, then plunged by 85.23% to $2.5 million in 2023, then surged by 448.85% to $13.9 million in 2024, then slumped by 99.28% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
- Business Quant data shows SLS's Cash & Equivalents at $100000.0 in Q1 2026, $100000.0 in Q4 2025, and $44.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 44.32 Mn |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 13.89 Mn |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 2.53 Mn |
| Sep 30, 2023 | 3.97 Mn |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 23.90 Mn |
| Dec 31, 2022 | 17.13 Mn |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 21.36 Mn |
| Sep 30, 2021 | 26.30 Mn |
| Jun 30, 2021 | 100,000.00 |